Dabigatran has been associated with an increase in acute coronary events when compared with warfarin in several randomized trials, and now in a meta-analysis by Uchino and Hernandez. We critically ...

HAMILTON, ON — In a multicenter Canadian study of more than 500 patients who had to have dabigatran (Pradaxa, Boehringer Ingelheim) therapy interrupted when they underwent major or minor surgery, ...

Dabigatran linked to lower incidence of bleeding events in atrial fibrillation Anticoagulation with dabigatran was associated with fewer bleeding complications compared with warfarin among patients ...

Test results presented have implications for patients if they require emergency surgery. Last month, the FDA approved idarucizumab (marketed as Praxbind) as an agent that specifically reverses the ...

Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. In this ...

BETHESDA, MD — The US Food and Drug Administration is requesting input from the public on a proposed study that will assess safety outcomes in adults with atrial fibrillation who recently started ...

Please provide your email address to receive an email when new articles are posted on . Dabigatran is an oral anticoagulant - a synthetic thrombin inhibitor – that is approved in the United States for ...

In two trials exploring potential new indications, dabigatran (Pradaxa; Boehringer Ingelheim) failed to show significant advantages over standard treatments for embolic stroke of undetermined source ...

Approximately 1 in 4 patients with nonvalvular atrial fibrillation (A-fib) who are prescribed dabigatran do not take it as directed and are therefore at increased risk for adverse clinical events, ...

Ascend Laboratories has recalled 10 lots of Dabigatran Etexilate capsules, used to lower the risk of blood clots and strokes, after finding the nitrosamine in the drug was above the FDA’s acceptable ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of dabigatran etexilate for the prevention of VTE after elective total hip or knee replacement surgery in ...

Ascend Laboratories LLC. has recently issued a nationwide recall of Dabigatran Etexilate Capsules. USP 75 mg and 150 mg over concerns about the presence of nitrosamine (N-Nitroso-Dabigatran). It is ...